© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Cardiff Oncology, Inc. (CRDF) shows an Average True Range (ATR) of 0.17 and an Enterprise Value of 167.24M. Its average trading volume over the past 3 months is 879.94K, indicating liquidity. These fundamental metrics provide insight into CRDF's underlying financial health and market activity.
Cardiff Oncology, Inc. (CRDF) technical indicators as of December 31, 2025: the SMA 20 is 13%, SMA 50 at 23.03%, and SMA 200 at 3.99%. The RSI 14 value is 62.7, suggesting its current momentum. These technical analysis signals help assess CRDF's price trends and potential future movements.
Cardiff Oncology, Inc. (CRDF) stock performance overview as of December 31, 2025: The 52-week high is $4.99 (currently -42.48% below), and the 52-week low is $1.9 (currently 51.05% above). Over the past year, CRDF's performance is -29.48%, compared to the S&P 500's 11.81% change.
According to market data, Cardiff Oncology, Inc. (CRDF) stock's recent performance metrics show that over the last month, CRDF is 22.65%, with a Year-to-Date (YTD) performance of -33.87%. Over the past year, the stock has seen a -29.48% change. These figures summarize CRDF's price movements across various periods, reflecting its historical returns.
According to current financial data, CRDF stock's P/E (TTM) ratio is -4.20, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CRDF, including P/S (560.14), P/B (4.35), and P/FCF (-5.05), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.